1. Generics Bulletin
  2. >>Policy & Regulation

AAM Condemns ‘Build Back Better 2.0’ Due To Off-Patent Impact

US Draft Drug Legislation Could Complicate Market Entry For Generics And Biosimilars

 
• By Chloe Kent

The Association for Accessible Medicines has criticized draft legislation regarding US drug pricing negotiations for the impact proposed new laws could have on generic and biosimilar drugs.

Senator Joe Manchin is confronted by climate activists leaving his boat on his way to Capitol Hill
Build Back Better crumbled last year after Joe Manchin refused to vote for the legislation • Source: Shutterstock

The US Association for Accessible Medicines has spoken out against draft legislation released by the Senate Finance Committee on 6 July, which largely rehashes the key provisions in a package agreed to by congressional Democrats last year, save for a few updates. The AAM has argued that the new bill does not do enough to protect incentives for developing biosimilars or generic drugs.

The Democratic administration initially hoped to include drug price reform as part of its larger Build Back Better bill, which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

Medicines For Europe Sets Out Trade Priorities

 
• By Dave Wallace

As Medicines for Europe gears up for a pair of conferences in Brussels next week, the organization has set out trade policy recommendations to strengthen access to medicines and the competitiveness of EU manufacturing, in a seminar with representatives from the European Commission and member states.

Canada Joins Global Push To Drop Costly Clinical Trials For Biosimilars

 
• By Neena Brizmohun

Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.

Beyond ‘Vanilla’ Generics: How Lupin Is Evolving To Stay Ahead Of The UK Competition

 
• By Dave Wallace

As UK players face increasing competitive pressures on “vanilla” generics – including potential new market entrants from China – Ben Ellis, Lupin’s UK and Ireland general manager, explains how the company is focusing on more complex opportunities that require a hybrid generic and branded mindset.

IGBA Asks G7 To Consider Access Issues

 
• By Dave Wallace

The International Generic and Biosimilar medicines Association has set out three priority areas that it says should be considered by G7 leaders at the current summit in Alberta, Canada, as part of efforts towards ensuring access to health.

More from Generics Bulletin